End Stage Renal Disease Market Size, Key Companies, Company Market Share, Patient Volume, Treatment Adoption Rates, Pricing Analysis, Regulatory Landscape, Competitive Positioning, and Demand Forecast

Revenue, 2026

USD 174.43 Bn

Forecast Year, 2035

USD 531.76

CAGR, 2026 - 2035

13.21%

Report Coverage

Global

What is the End Stage Renal Disease Market Size?

The global end stage renal disease market size is calculated at USD 153.72 billion in 2025 and is predicted to increase from USD 174.43 billion in 2026 to approximately USD 531.76 billion by 2035, expanding at a CAGR of 13.21% from 2026 to 2035. The market is driven by the rising global prevalence of chronic conditions such as diabetes and hypertension, which directly cause kidney damage. An aging population leads to a surge in patients demanding dialysis or transplants, thereby boosting the need for renal care products and services. The end-stage renal disease market is driven by rising chronic kidney disease, diabetes, hypertension, and demand for dialysis and transplantation.

End Stage Renal Disease Market Key Takeaways

• Asia Pacific contributed more than 39% of revenue share in 2025.
• By Treatment, the dialysis segment dominated the market with the largest market share of 79% in 2025.
• By Treatment, the transplant segment is expected to expand at the fastest CAGR from 2026 to 2035.

Market Overview

The global end stage renal disease market offers solutions, treatments, diagnosis services and other healthcare services for kidney-related health conditions that can cause terminal renal failure which can be irreversible. End-stage renal diseases occur when the kidneys' ability to function on their own is severely compromised. Dialysis or a kidney transplant is required for a patient with end-stage renal failure to live more than a few weeks. The number of patients with end-stage renal disease is expected to increase, driving market trends. A large number of people are affected by end stage renal disease, with chronic kidney disease being one of the main reasons. According to the National Center for Chronic Disease Prevention and Health Promotion's statement, approximately 15% of adults in the United States have chronic kidney disease.

End Stage Renal Disease Market Growth Factors

• The end stage renal disease market is anticipated to expand significantly due to an increase in kidney failure patients and the availability of technologically improved equipment like artificial kidneys and low-maintenance dialysis machines.
• End stage renal disease patients are becoming more dependent on dialysis as their main form of treatment because there are fewer kidney transplants available. The need for dialysis services and associated equipment has expanded as a result.
• Growing public awareness of renal health and the significance of kidney disease early diagnosis has resulted in earlier diagnosis and intervention, further propelling market expansion.

Strategic Growth Opportunities

• High Growth Commercial Opportunities: Needs for dialysis, home dialysis, and certain specialized dialysis centers are increasing, and this offers significant commercial opportunity. To expand care services and dialysis, CKD management, and value-based care programs has an opportunity.
• Emerging Technology Opportunities: There are chances of technology expansion in patient monitoring systems, remote dialysis management, wearable devices, and automatic dialysis systems. New technology and advanced treatment of ESRD, such as the bioengineered kidney, might further alter the treatment of ESRD.
• Geographic Expansion Opportunities: For dialysis providers and medical device companies, new markets with a high prevalence of diabetes, hypertension, and CKD may be lucrative new opportunities. The emerging healthcare markets, such as Saudi Arabia and Brazil, offer opportunities for growth in the renal-care market.

Future Outlook and Strategic Recommendations

• Long-Term Industry Outlook: With the increasing incidence of chronic diseases, an ageing population, and the increasing demand for renal replacement therapies, the ESRD market is expected to expand. The focus on early detection, home therapy, cutting-edge transplantation techniques, and tailored care going forward.
• Emerging Business Models: There are multiple recurring revenue opportunities like EndPoint Dialysis-as-a-service, home-care subscriptions, remote monitoring, and integrated chronic kidney disease (CKD) management. This can also be provided through public/private partnerships and Public Health Service Association (PHS) models.
• Strategic Recommendations for Stakeholders: Business investments and strategies going forward should include those areas where business is transitioning to home dialysis, increasing dialysis affordability, digital health, and advanced renal technologies that involve AI monitoring for dialysis.

Technology & Innovation

• Major Technologies: Vascular access devices, dialysis machines, dialyzers, peritoneal dialysis, and hemodialysis are key components of the ESRD market. Various portable treatment technologies and home dialysis systems are enhancing treatment flexibility and access to treatment.
• Emerging Innovations: Innovations in the monitoring of dialysis, wearable kidneys, remote dialysis monitoring, and bioengineered kidneys. The technologies aim to make treatment more individualised and to reduce possible complications and other benefits for the patients.
• R&D Trends: They are focused on the development of compact dialysis systems, improved dialysis membranes, biocompatibility issues, and automated dialysis therapy. Working on bioengineered kidney solutions and regenerative medicine as alternatives.
• Technology Adoption: Connected dialysis machines, digital patient monitoring systems, and automated systems are being used in hospital and dialysis settings. The visibility of home dialysis has been increasing, along with the trend of the healthcare industry to become more patient-centered and convenient.
• Impact on Market Growth and Competitiveness: Technological advancements can enhance the effectiveness of the treatment, patient observation, productivity, and long-term care of the disease. Companies that are more diversified with technology, digital platforms that are integrated with the technology, and innovative approaches to kidney care solutions are going to have more competitive prominence.

Market Attractiveness

• Growth Prospects: Prospects in the ESRD sector are good due to greater diabetes, hypertension, chronic kidney disease, and aging populations. Expansion in the long-term remains likely because there continues to be a growing demand for dialysis and kidney transplants.
• Demand Outlook: Hemodialysis will remain in demand, as well as peritoneal dialysis, dialysis equipment, and renal care. The rising trend of patients undergoing diagnosis and workup for kidney diseases and increasing access to healthcare is also driving the patient population. The increasing diagnosis of kidney diseases and increased access to healthcare are also contributing to growing the patient pool.
• Investment Potential: Including dialysis centers, home dialysis, digital health, and advanced renal-care technologies, the market is offering promising investment opportunities. Improvements in technologies such as neuro-monitoring, dialysis on-the-go, and bioengineered organs could create new market opportunities for the infused AI computer system.
• Future Opportunities: There are many areas of opportunity for growth, including home dialysis, remote patient monitoring, patient-centred solutions, and advanced transplantation solutions. Market support by exploiting the pipeline growth and investments into new renal-care facilities in emerging markets can further boost future market potential.

Market Scope

Market Dynamics

Driver

Aging population

The market for treatments for end-stage renal disease (ESRD) is significantly impacted by the aging population. According to WHO, by 2030, 1 in 6 individuals worldwide would be 60 years of age or older. The prevalence of kidney-related disorders including ESRD tends to rise when countries around the world experience demographic shifts with more people living longer. Medical gadget producers, pharmaceutical firms, and healthcare systems all must consider the effects of this demographic shift.

Elderly people are more prone to chronic diseases including diabetes and hypertension, both of which are major contributors to end stage renal disease (ESRD). If these disorders are not treated effectively, they may develop to more severe stages, causing kidney damage and ultimately ESRD. Older people are more susceptible to kidney-related problems because of the aging process itself, which contributes to the reduction of kidney function.

Medical services, such as ESRD diagnosis, treatment, and management, are in higher demand as the older population rises. Healthcare professionals adjust to older patients' unique needs, which frequently necessitate more extensive and long-term care. This includes having access to renal replacement therapies like dialysis or transplantation as well as drugs specially formulated to address the physiological changes experienced by aged people.

Pharmaceutical firms are motivated to provide medications that address the particular difficulties of treating ESRD in elderly patients, taking into account elements including numerous comorbidities, drug interactions, and frailty. Manufacturers of medical equipment are also motivated to develop technologies that are user-friendly for elderly patients, such as remote monitoring systems that let seniors get treatment in the comfort of their homes or dialysis devices that are simpler to operate.

Restraint

High-cost treatment

The high expense of treating end stage renal disease (ESRD) is one of the main obstacles to controlling this condition, which presents a significant healthcare issue. Renal replacement therapy, primarily in the form of dialysis or kidney transplantation, is often required for ESRD. Although these therapies are necessary for ESRD patients to survive, they come at a significant financial cost to both patients and healthcare systems.

The common treatment for ESRD, dialysis, is a time- and resource-consuming procedure. The majority of ESRD patients must have regular dialysis treatments for the remainder of their lives, frequently many times each week. These sessions require expensive overhead, specialized medical staff, and complex technology.

As a percentage of total healthcare spending, Medicare dialysis costs in the United States average around $60,000 per patient. As the long-term cost of dialysis is high, individuals without appropriate health insurance may find it especially difficult to afford treatment.

While a longer-term alternative to dialysis that is more cost-effective, kidney transplantation nevertheless entails high costs. The cost of the operation, the immunosuppressive drugs required after the transplant to avoid organ rejection, and continuing monitoring and care are also factors. Furthermore, there is frequently a long waiting list for kidney transplants, and some patients may have to travel a great distance for the procedure, adding to the expense. Moreover, these high treatment costs for ESRD affect not only the individuals suffering from the condition but also strain healthcare systems and insurance providers. Dialysis and transplant services account for a significant portion of healthcare budgets in many countries. This financial strain can limit the capacity of healthcare systems to provide timely and comprehensive care to all ESRD patients.

Opportunity

Demand for home-based dialysis

Home-based dialysis is a fast-expanding trend in end-stage renal disease (ESRD) therapy, providing both patients and healthcare professionals with a number of opportunities. The majority of ESRD patients have historically received hemodialysis at dialysis centers as their primary form of dialysis care. However, home-based dialysis techniques, such as peritoneal dialysis and home hemodialysis, are becoming more and more common for a number of reasons. Home-based dialysis allows patients to get treatments in the comfort of their own homes, removing the need for frequent travel to dialysis facilities. Patients and their carers' workload are lessened, and their general quality of life is enhanced.

Patients on home-based dialysis have more flexibility in scheduling their treatments. They can choose the timing and frequency of dialysis sessions that best fit their lifestyles, making it easier to maintain employment and engage in daily activities. In the long term, home-based hemodialysis may be less expensive than in-centre hemodialysis. Potential cost reductions for healthcare organizations and payers can be attributed to lower overhead expenses like staffing and facility maintenance. Thus, the rising demand for home-based dialysis is observed to offer an opportunity for the market to expand.

Segmental Insights

Treatment Insights

The dialysis segment had the greatest share, and it is anticipated that it would continue to dominate during the forecast period. The main driver is the increasing incidence of end-stage renal disease (ESRD) and chronic kidney disease (CKD). Globally, risk factors for kidney disease from lifestyle variables like obesity, diabetes, and hypertension are on the rise. As a result, the number of patients in need of renal replacement therapy, such as dialysis, is increasing.

Technology and medical technique advancements are also crucial. Hemodialysis and peritoneal dialysis equipment advancements, as well as the creation of at-home dialysis options, have increased patient accessibility and convenience. The use of telehealth and remote monitoring devices has also improved patient care and lessened the stress of regular in-person clinic appointments.

In the global market, the transplant segment is seen as having the fastest rate of growth. The need for kidney transplants has increased as a result of the rising prevalence of chronic kidney disease (CKD), which frequently causes ESRD. The rising prevalence of CKD is a result of aging populations and lifestyle variables such poor diet and inactivity.

The success rates of kidney transplants have also greatly increased as a result of medical innovations in immunosuppressive medications and surgical methods. These developments make transplantation a more appealing choice by lowering the possibility of graft rejection and improving patient outcomes. The demand of transplant has increased due to the scarce supply of donor organs.

Due to the lack of organs, there are now more efforts being made to encourage organ donation and improve organ allocation procedures. Governments around the world have put laws in place to encourage organ donation and transplantation after realizing the value of transplantation in the management of ESRD. Market expansion has been further encouraged by financial support and incentives for both donors and receivers.

Regional Insights

Asia Pacific End Stage Renal Disease Market Size and Growth 2026 to 2035

The Asia Pacific end stage renal disease market size is exhibited at USD 59.95 billion in 2025 and is projected to be worth around USD 213.94 billion by 2035, poised to grow at a CAGR of 13.57% from 2026 to 2035.

How did Asia Pacific dominate the End Stage Renal Disease Market?

Asia Pacific dominated the market in 2025, the region is expected to continue to grow at a significant rate during the forecast period due to a number of important factors. The number of people with ESRD has grown as a result of the rising incidence of diabetes and chronic kidney disease (CKD), which are major risk factors for the condition. The number of CKD-related ESRD cases increases as urbanization, aging population, and changes in lifestyle persist. Bettering healthcare systems and access to renal care facilities in many Asia Pacific countries have made it possible to detect ESRD earlier and manage it better. This has led to an increase in the need for kidney transplants as well as renal replacement therapies like hemodialysis and peritoneal dialysis.

China Market Trends

China is a major contributor to the Asia Pacific end stage renal disease market due to its large population and high prevalence of chronic kidney disease driven by diabetes and hypertension. The country's expanding dialysis infrastructure and increasing government investment in renal care services support market growth. Additionally, rising awareness and improving access to treatment further strengthen China's leading position in the regional ESRD market.

A larger percentage of the population may now receive modern ESRD treatments due to increased disposable incomes in various Asian countries. Modern dialysis equipment, medications, and transplant procedures have all been funded by rising healthcare costs, both public and private.

What Makes North America the Fastest-Growing Region in the Market?

North America is expected to have the fastest rate of growth as a result of a convergence of demographic changes, technological advances in medicine, and changes in healthcare regulations. These elements are altering the ESRD care landscape and stimulating market growth. Aging populations are a major factor in the rise of ESRD, according to demographic trends. Chronic diseases like diabetes and hypertension, which can result in kidney damage, are becoming more common as the Baby Boomer population ages. This rise in at-risk individuals results in a larger pool of ESRD patients. When it comes to medical technology innovation, North America has been on the cutting edge. This is demonstrated in the ESRD industry by the advancement of patient-friendly, more effective dialysis equipment as well as at-home dialysis solutions like peritoneal dialysis. These breakthroughs improve patient outcomes, lighten the load on healthcare institutions, and stimulate market expansion.

U.S. Market Trends

The U.S. end stage renal disease market is driven by the high prevalence of diabetes and hypertension, which are the leading causes of kidney failure. An aging population and increasing incidence of chronic kidney disease further fuel demand for dialysis and renal replacement therapies. Additionally, advanced healthcare infrastructure and favorable reimbursement policies support continued market growth.

Europe A Notably Growing Region

Europe is considered a notably growing region in the end stage renal disease market due to the rising prevalence of chronic kidney disease driven by aging populations and lifestyle-related conditions such as diabetes and hypertension. Strong healthcare systems and widespread access to dialysis and renal care services support early diagnosis and treatment. Additionally, government initiatives and reimbursement frameworks promoting advanced renal therapies are contributing to steady market growth across the region.

Germany Market Trends

The market in Germany is driven by a growing aging population and the high prevalence of diabetes and hypertension, which are leading causes of kidney failure. Germany's well-established healthcare system and broad access to advanced dialysis and renal care services support sustained demand. Additionally, favorable reimbursement policies and strong adoption of innovative renal treatment technologies contribute to market growth.

What Made Latin America hold a considerable share of the End Stage Renal Disease Market?

Latin America is expected to experience significant growth in the market due to the shift to cost-effective treatments, the adoption of AI-driven remote monitoring and telemedicine, which improve early detection of diseases and patient adherence. The major government programs and policy updates in this region are Mexico's Alliance for Kidney Health, Brazil's SUS Budget Increase, and the WHO Landmark Resolution.

What is the Potential of the End Stage Renal Disease Market in the Middle East and Africa?

The Middle East and Africa are expected to grow at a lucrative rate in the market, driven by the strategic expansion of global healthcare players, the national healthcare programs, the adoption of home-based dialysis, and advancements in digital health platforms. The government-backed healthcare reforms, the implementation of clinical practice guidelines, and the WHO resolution on kidney health contribute to the regional expansion.

Competitive Landscape

The end-stage renal disease market is divided between healthcare firms and an array of renal care specialists trading in arteries, dialyzers, access devices, renal therapies and services. The prominent players are Nipro Corp., Fresenius Medical Care AG & Co. KGaA, Baxter International, Inc., Medtronic Plc, and B. Braun Melsungen AG, which have strong global brands and presence and also have strong renal-care portfolios.

Key players are engaging in product innovation, at-home dialysis and integrated treatment, and digital health approaches to help bolster market position. Growth drivers such as continued rising rates of ESRD, demand for effective treatments that are low cost, and other technological advances are factors of competition, while strategic partnerships, investment, and geographic expansion power company growth.

Company Profiles - End Stage Renal Disease Market

Nipro Corp.

Headquarters: Osaka, Japan

Founded: 1954

Nipro Corp. has long been known for its discoveries and leading Kewaunee Drainage products in renal care. It provides hemodialysis machines, blood tubing systems, dialysis machines, blood/dialysis solution, and other products in the field of hemodialysis therapy. It has a large product variety along with a manufacturing/distribution network around the world.

• Key Strengths: Wide range of renal care products, good manufacturing capacities, dialysis experience, global presence, and investments in healthcare technologies.
• Key Vulnerabilities: The global dialysis producers as well as integrated renal-care service providers are very competitive with Nipro. Its growth and profitability could be impacted due to pricing pressures, regulatory mandates, and the need for ongoing product innovation.

Fresenius Medical Care AG & Co. KGaA

Headquarters: Bad Homburg, Germany

Founded: 1996

Fresenius Medical Care is one of the world's leading manufacturers and suppliers of products and services to individuals with chronic kidney failure. It offers dialysis machines, dialyzers, and disposables to address the value chain of dialysis care services and brings home dialysis technologies to the market. Its vertically integrated business model that centers on the patient and its presence in dialysis facilities all over the world.

• Key Vulnerabilities: Small production capacity, very inflexible pricing, lack of geographic infrastructure and brand recognition, comparatively small network of dialysis centers, and substandard customer knowledge in launching products.

Baxter International, Inc.

Headquarters: Deerfield, Illinois, USA

Founded: 1931

Baxter International Inc. is a diversified healthcare company with experience in a range of kidney services, including Peritoneal dialysis and In-Home Renal Services. It has a track record spanning automated peritoneal dialysis machines, dialysis solutions, as well as other items for people not in the dialysis center. Baxter's skills in the healthcare sector and its global distribution network have helped it maintain its position in the renal care sector.

• Key Strengths: The company has the requisite expertise to develop healthcare skills, solid experience in medical devices, a global distribution system, and success in home dialysis.

Medtronic Plc

Headquarters: Dublin, Ireland

Founded: 1949

Medical-technology firm Medtronic is part of the ESRD system primarily in the area of vascular-access devices utilized by patients receiving dialysis. It's also well-versed in minimally invasive devices, vascular technologies, and clinical trials to aid access for hemodialysis therapy products. The healthcare segment opportunity may lie in the company's worldwide presence in the healthcare industry, allowing for the development of special technologies in renal care.

Key Vulnerabilities: Medtronic's dialysis system and renal-care business is smaller than similar businesses at other firms. Therefore, the opportunities for this market depend on the need for vascular-access procedures and associated technologies.

B. Braun Melsungen AG

Headquarters: Melsungen, Germany

Founded: 1839

Braun Melsungen AG is a conglomerate company with experience in medical devices and renal-care technologies. It offers its customers a variety of products such as dialysis machines and dialyzers, dialysis solutions including treatment types and blood tubing systems, vascular-access products, and other products for renal replacement therapy. The healthcare company has a diverse spectrum of products and services and a global reach, making it possible to serve patients in hospitals, dialysis facilities, and healthcare centers worldwide.

• Key Strengths: Wide range of dialysis portfolio with proven experience in medical-device expertise, manufacturing capabilities, global presence, diversified vertical product offers in healthcare.

Value Chain Analysis of the End Stage Renal Disease Market

• R&D
  This stage includes device innovations such as wearable artificial kidneys, portable peritoneal dialysis, and bioartificial and implantable organs.
  Key Players: Fresenius Medical Care, DaVita Inc., Medtronic, Baxter International, AWAK Technologies.
• Distribution to Hospitals, Pharmacies
  This stage is expanding due to inventory management, add-on payments, cold-chain and specialized handling, and the Drug Supply Chain Security Act (DSCSA).
  Key Players: Fresenius Medical Care, Vantive, Nipro Corporation, B. Braun Melsungen AG, Asahi Kasei
• MedicalCardinal Health, Medline Industries.
  Patient Support & Services
  This stage involves integrated care teams, home dialysis management, value-based care coordination, and more.
  Key Players: Diaverum, Dialysis Clinic, Inc., Outset Medical, Satellite Healthcare, Vantive, NephroPlus, U.S. Renal Care, Fresenius Medical Care.

End Stage Renal Disease Market Companies

• Nipro Corp.
• Fresenius Medical Care AG & Co. KGaA
• Baxter International, Inc.
• Medtronic Plc
• B. Braun Melsungen AG
• BD
• Asahi Kasei Medical Co., Ltd.
• Cantel Medical
• Nikkiso Co., Ltd.
• JMS Co. Ltd.

Collaboration Landscape

• In February 2026, Lana Company collaborated with Kidney Care Company to set up and manage specialised dialysis centres in Saudi Arabia. The deal will initially be carried out in Riyadh, and then be rolled out to other regions in a phased manner. (Source: https://www.saudiexchange.sa)
• In November 2025, Nextkidney, Fakeeh Care Group and SaudiVax joined forces to co-develop bioengineered kidney technology. The collaboration will further be dedicated to the localization of health services in Saudi Arabia and increasing the innovation of medical services in the area. (Source: https://nextkidney.com)

Recent Developments

• In September 2022, Cytecare, Bengaluru announced the launch of state-of-the-art dialysis centre for the treatment of kidney-related diseases. With the launch of this centre, Cytecare aims to advance its holistic approach towards healthcare services.
• In May 2023, a private, last-stage biopharma company, Pathalys Pharma announced its first patient enrolled ahead of schedule in pivotal phase program, designed for hemodialysis.
• In January 2023, according to Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY), the U.S. Food and Drug Administration (FDA) has approved a supplement new drug application for Jardiance tablets, which is being researched as a potential treatment to lower the risk of kidney disease progression and cardiovascular deaths in adults with chronic kidney disease.
• In June 2025, Fresenius Medical Care launched its Strategy FME Reignite, which aims to lead kidney care through excellent patient care and innovation. The plan introduces a new capital allocation framework to enhance value creation.
  Source: https://freseniusmedicalcare.com

Segments Covered in the Report

By Treatment

• Transplant
• Dialysis

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa